Revenue
2022
2023
2024
2025
PDS Biotechnology Corp (PDSB)
Price$0.3153Cached quote
Net income
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2013
2014
2015
2016
2017
2018
2023
2024
2025
Total cash / debt
CashTotal debt
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | — | — | — | — | — | — | — | — | — |
| Research & development | $19.0M | $22.6M | $27.8M | $29.4M | $11.3M | $7.9M | $6.1M | $830,744 | $34.3M | $24.8M | $17.8M | $8.5M | $4.5M |
| Operating expenses | $31.5M | $36.3M | $43.0M | $41.7M | $21.4M | $14.9M | $21.0M | $3.6M | $52.0M | $39.5M | $26.5M | $13.2M | $6.5M |
| Operating income | −$31.5M | −$36.3M | −$43.0M | −$41.7M | −$21.4M | −$14.9M | −$21.0M | −$3.6M | −$52.0M | −$39.5M | −$26.5M | −$13.2M | −$6.5M |
| EBITDA | −$31.5M | −$36.3M | −$43.0M | −$41.6M | −$21.4M | −$14.9M | −$20.9M | −$3.6M | −$51.8M | −$39.4M | −$26.4M | −$13.2M | −$6.5M |
| Net income | −$34.5M | −$37.6M | −$42.9M | −$40.9M | −$16.9M | −$14.8M | −$7.0M | −$3.8M | −$50.9M | −$38.8M | −$28.1M | −$12.2M | −$6.9M |
| Basic EPSper basic share | -$0.74 | -$1.03 | -$1.39 | -$1.43 | -$0.66 | -$0.89 | -$1.44 | $1.15 | — | — | — | — | — |
| Diluted EPSper diluted share | -$0.74 | -$1.03 | -$1.39 | -$1.43 | -$0.66 | -$0.89 | -$1.44 | $1.15 | — | — | — | — | — |
Owners
Reported shareholders
3.04%of listed shares
VANGUARD CAPITAL MANAGEMENT LLC1.7M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
VANGUARD CAPITAL MANAGEMENT LLC | 3.04%1.7M shares |
Focus Partners Wealth | 1.15%642.18K shares |
Quantinno Capital Management LP | 1.15%642.18K shares |
BlackRock, Inc. | 1.09%607.64K shares |
GEODE CAPITAL MANAGEMENT, LLC | 1.05%587.14K shares |
VANGUARD FIDUCIARY TRUST CO | 0.64%357.14K shares |
Militia Capital Management LLC | 0.59%331.8K shares |
CITADEL ADVISORS LLC | 0.58%323.8K shares |
MORGAN STANLEY | 0.56%313.92K shares |
BLAIR WILLIAM & CO/IL | 0.54%300K shares |
JANE STREET GROUP, LLC | 0.50%279.66K shares |
RENAISSANCE TECHNOLOGIES LLC | 0.45%252.2K shares |
INSPIRION WEALTH ADVISORS, LLC | 0.34%189K shares |
MARSHALL WACE, LLP | 0.26%147.17K shares |
STATE STREET CORP | 0.24%133.33K shares |
NORTHERN TRUST CORP | 0.23%126.5K shares |
WELLS FARGO & COMPANY/MN | 0.19%109K shares |
COMMONWEALTH EQUITY SERVICES, LLC | 0.17%93K shares |
Glover Stephen C. | ≈0.14%78.85K shares |
Iron Gate Global Advisors LLC | 0.13%70.41K shares |
Percentages use 55.92M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Feb 28, 2025Form 4 | Freitag Gregory GeneDirector | BuyCommon Stock | 15.1K | $1.66 | $25.0K | 61.2K |
| Feb 28, 2025Form 4 | Freitag Gregory GeneDirector | BuyCommon Warrant · derivative | 15.1K | — | — | 15.1K |
| Feb 28, 2025Form 4 | Glover Stephen C.Director | BuyCommon Stock | 15.1K | $1.66 | $25.0K | 78.9K |
| Feb 28, 2025Form 4 | Glover Stephen C.Director | BuyCommon Warrant · derivative | 15.1K | — | — | 15.1K |